Upcoming events

Follow Us

Menu
Log in
Forgot password


Alabama Society of Health-System Pharmacists

Log in

Policies, Guidelines, & Protocol Sharing

  • Tue, August 05, 2025 11:57 AM
    Quote
    Reply # 13528529 on 13511084
    Anonymous member

    Thanks for the reply Leborah!  We are trying to move forward with restrictions to just stable HF patients.  We will see how this turns out.
  • Wed, July 23, 2025 1:34 PM
    Quote
    Reply # 13524066 on 13511084
    Anonymous member (Administrator)

    At EAMC, we do not have any restrictions, but we just performed an MUE. Over 90% of these patients did not have the medication help appropriately around surgery. Our formulary agent is dapagliflozin based on the number of indications and cost for our health-system. 
  • Wed, July 16, 2025 9:41 PM
    Quote
    Reply # 13521661 on 13511084
    Anonymous member

    Good evening!  Our cardiology group at Baptist South is seeking to add an SGLT2 Inhibitor to formulary with the intention of ordering new therapy starts on heart failure patients while inpatient.  I am curious what other facilities in the state are doing as far as choice of formulary agent as well as any restrictions/criteria for use that are in place.  Thanks!
  • Tue, June 17, 2025 6:25 AM
    Quote
    Message # 13511084
    Anonymous member (Administrator)

    This is a space for pharmacists to share institution-specific policies, guidelines, and protocols related to clinical practice. Whether it’s antimicrobial stewardship, anticoagulation management, order sets, or order verification workflows, share your tools/resources and learn from others across the state.
Powered by Wild Apricot Membership Software